Charting FDA’s recent progress and ongoing campaigns in NGS dx. FDA has solidified its commitment to advancing genetic dx.. is turning to software variability across NGS systems, limitations of liquid biopsies and detection of low-frequency variants.biocentury.com/bc-innovations